Humacyte Receives Nasdaq Delisting Notice for Failing Listing Rule

Humacyte Inc. told the SEC on May 8 2026 that it had received a notice from Nasdaq stating the company no longer meets a listing requirement.

The filing covers the entire company, which maintains its common stock listing on Nasdaq under CIK 0001818382. The notice identifies a specific listing rule violation but does not quantify dollar impact or share volume in the document.

Prior to the notice Humacyte maintained compliance with all applicable Nasdaq continued-listing standards and traded without a delisting warning. The new state is formal non-compliance under Item 3.01, with the company now required to submit a plan or take corrective action within the cure period specified by Nasdaq rules.

The change took legal effect on the date the notice was received, prior to the May 8 filing.

The notice triggers a sequence of regulatory deadlines. Humacyte must either regain compliance within the standard 180-day cure window or request a hearing before a Nasdaq hearings panel, which would stay any immediate suspension. Failure to cure or obtain an extension obliges the exchange to issue a delisting determination, after which the company would have to file additional Form 8-K disclosures and consider moving to over-the-counter trading.

The delisting process also affects the company’s obligations under its existing SEC registration and could require updates to contracts that reference Nasdaq-listed status.

This marks the first such Item 3.01 notice filed by Humacyte since its public listing. The Form 8-K is the official SEC record and contains no additional exhibits detailing the exact rule violated or the cure timeline beyond the standard Nasdaq procedures referenced in Item 3.01.